Huons Co., Ltd. (KOSDAQ:243070)

Market Cap	306.44B +1.2%
Revenue (ttm)	602.21B +2.3%
Net Income	35.75B +0.6%
EPS	2,985.83 +5.8%
Shares Out	11.65M
PE Ratio	8.81
Forward PE	n/a
Dividend	920.00 (3.55%)
Ex-Dividend Date	Apr 2, 2026

Volume	15,507
Average Volume	27,753
Open	26,200
Previous Close	25,900
Day's Range	25,600 - 26,500
52-Week Range	23,100 - 32,200
Beta	0.06
RSI	45.80
Earnings Date	Mar 25, 2026

About Huons

Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1965
• Employees: 912
• Stock Exchange: KOSDAQ
• Ticker Symbol: 243070

Financial Performance

In 2024, Huons's revenue was 590.23 billion, an increase of 6.92% compared to the previous year's 552.01 billion. Earnings were 29.45 billion, a decrease of -41.64%.